Another novel drug targeting the IL-23/IL-17 axis via targeting of an IL-23 subunit is risankizumab, which binds to the p19 subunit of IL-23, and has been shown to be effective in CD [262, 263]. The gene discussed is IL23A; the disease is Cowden disease.